Posted by Michael Wonder on 05 Sep 2025
Ulcerative colitis: comparative study provides important insights
2 September 2025 - The data show no additional benefit of guselkumab compared to golimumab.
The human monoclonal antibody guselkumab has been approved for certain adults with moderate to severe active ulcerative colitis since April 2025. In a benefit assessment, the IQWiG has now examined whether guselkumab offers an additional benefit for these patients.
